top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


21/04/2026










Phase 3 LITESPARK-012: Triplet and Doublet Regimens Fail to Surpass KEYTRUDA + LENVIMA in Advanced RCC (Ref)


Merck & Co. and Eisai announced that their Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for first-line treatment of advanced clear cell RCC. Both experimental combination regimens — KEYTRUDA + LENVIMA + WELIREG and MK-1308A + LENVIMA — failed to outperform the established KEYTRUDA plus LENVIMA standard of care


  • Safety profiles were consistent with prior studies


  • Full data analysis is ongoing; results will be shared with the scientific community




bottom of page